Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group:venlafaxine-XR, 75mg, oral capsules, 2 times daily, for 8 weeks. Intervention 2: Control group, placebo: oral capsules contain starch with the same weight and simila
2 times daily for 8 weeks.
Treatment - Drugs
Placebo
Intervention group:venlafaxine-XR, 75mg, oral capsules, 2 times daily, for 8 weeks.
Control group, placebo: oral capsules contain starch with the same weight and similar shape with drug
Sponsors
Kurdistan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria (1)-DSM-IV diagnosis for shizophrenia. (2)-Age between 18-59 years old. (3)-Not presenting of moderate to severe depression according to the beck depression inventory. (4)-Total PANSS Sc ore>60. (5)- Present of significant negative symptoms (PANSS negative sub score>20). (6)-Patient medication dose does not change during past 3 month of study. (7)-Patient's medications must be risperidone or olanzapin. (8)-Obtaining the written informed consent. Exclusion criteria: (1)-Additional diagnosis in axis 1 according to DSM-IV. (2)-Substance abuse or dependence except nicotine. (3)-Pregnant women. (4)-Women in fertility ages which does not use OCP. (5)-History of allergic reaction to venlafaxine. (6)-Giving ECT during previous 2 months. (7)- On methadone maintenance therapy. (8)-Patients with increased intra ocular pressure or in the risk of close angle glaucoma. (9)-Hepatic cirrhosis. (10)-Breast feeding women. (11)-Cimetidine consumption in the presence of HTN or hepatic impairment. (12)-Another psychotropic drugs consumption except benzodiazepins. (13)-Mental Retardation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of schizophrenia. Timepoint: Before study as baseline;4 weeks after beginning of study;6 weeks after beginning of study and 8 weeks after beginning of study. Method of measurement: PANSS inventory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: Before study as a baseline;4 weeks after beginning of study;6 weeks after beginning of study and 8 weeks after beginning of study. Method of measurement: ESRS inventory.;Severity of psychiatric symptoms. Timepoint: Before study as baseline;4 weeks after beginning of study;6 weeks after beginning of study and 8 weeks after beginning of study. Method of measurement: BPRS inventory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ehsan Salemi
Kurdistan University of Medical Sciences
Outcome results
None listed